Table 3.

Hypoglycaemia and serious adverse events during 18 months according to insulin regimens

				p Value
	Biphasic (n=137)	Aspart+detemir (n=138)	Detemir (n=137)	Biphasic vs aspart+detemir	Biphasic vs detemir	Aspart+detemir vs detemir
Severe hypoglycaemia (number of patients with at least 1 event, N (%))	3 (2.2)	5 (3.6)	6 (4.4)	0.4859	0.3205	0.7500
Severe hypoglycaemia (number of events (rate among patients with at least 1 event))	4 (1.3)	16 (3.2)	7 (1.2)	0.0141	0.3770	0.0707
Non-severe hypoglycaemia (number of patients with at least one event, N (%))	110 (80.3)	108 (78.2)	95 (69.3)	0.6778	0.0375	0.0927
Non-severe hypoglycaemia (number of events (rate among patients with at least 1 event))	2823 (25.7)	2570 (23.8)	2115 (22.3)	<0.001	<0.001	<0.001
Serious adverse events excluding severe hypoglycaemia (number of patients with at least 1 event, N (%))	37 (27.0)	31 (22.5)	31 (22.6)	0.3826	0.4072	0.9658
Serious adverse events excluding severe hypoglycaemia (number of events (rate among patients with at least 1 event))	64 (1.7)	45 (1.5)	44 (1.4)	0.0656	0.0588	0.9555

Severe hypoglycaemia is defined as a hypoglycaemic episode where help from a third person was needed.

Non-severe hypoglycaemia defined as an episode with either symptoms of hypoglycaemia and/or measurement of plasma glucose ≤3.9 mmol/L.